Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

Phase 2 Completed 28 enrolled Helse Stavanger HF University of Oslo · collab University of Stavanger · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Fatigue is a prevalent phenomenon in Primary Sjøgrens syndrome (PSS). Observations indicate that the cytokine IL-1 is of importance for this phenomenon. In this study the investigators block IL-1 by giving Anakinra (an IL-1 receptor antagonist) to patients with PSS.

Timeline

Start: 2008-01
Primary completion: 2010-04
Completion: 2010-04

Publications

Norheim KB, Harboe E, Goransson LG, Omdal R. Interleukin-1 inhibition and fatigue in primary Sjogren's syndrome--a double blind, randomised clinical trial. PLoS One. 2012;7(1):e30123. doi: 10.1371/journal.pone.0030123. Epub 2012 Jan 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Anakinra	Protein / enzyme biologic	100 mg	Subcutaneous

Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

Summary

Timeline

Publications

Drugs

Indications